30 Facts About Teva Pharmaceuticals


Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer.

FactSnippet No. 1,457,727

Teva Pharmaceuticals regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020.

FactSnippet No. 1,457,728

Teva Pharmaceuticals's facilities are located in Israel, North America, Europe, Australia, and South America.

FactSnippet No. 1,457,729

Teva Pharmaceuticals is a member of the Pharmaceutical Research and Manufacturers of America .

FactSnippet No. 1,457,730

Teva Pharmaceuticals's visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development.

FactSnippet No. 1,457,731

Later on, Teva Pharmaceuticals exported its products to the US, Soviet Union, health institutes in Denmark, Czechoslovakia, Persia and Burma.

FactSnippet No. 1,457,732

In 1954, Teva Pharmaceuticals received a Certificate Excellence in Training award from the Israeli President, Yitzhak Ben Zvi.

FactSnippet No. 1,457,733

In 1964, Teva Pharmaceuticals partnered with Sintex, a company from Mexico, and Schering Plough.

FactSnippet No. 1,457,734

In 1980, Teva Pharmaceuticals acquired Ikapharm, then Israel's second largest drug manufacturer.

FactSnippet No. 1,457,735

In 1982, Teva was granted approval by the U S Food and Drug Administration for its Kfar Saba manufacturing plant.

FactSnippet No. 1,457,736

In October 2003, Teva Pharmaceuticals announced its intentions to acquire Sicor Inc for $3.

FactSnippet No. 1,457,737

In 2005, Teva Pharmaceuticals opened a new, state-of-the-art pharmaceutical manufacturing plant in Har Hotzvim, a technology park in Jerusalem.

FactSnippet No. 1,457,738

Teva Pharmaceuticals entered the Japanese market in 2005, and in 2008 established a generics joint venture with Kowa.

FactSnippet No. 1,457,739

In March 2010, Teva Pharmaceuticals acquired German-based company Ratiopharm in a deal worth almost $5 billion, significantly expanding its European coverage.

FactSnippet No. 1,457,740

In October 2010, Teva Pharmaceuticals entered a licensing agreement with BioTime to develop and market BioTime's OpRegen for the treatment of age-related macular degeneration, an effort that in 2013 received $1.

FactSnippet No. 1,457,741

In January 2014, Teva Pharmaceuticals acquired NuPathe, after outbidding Endo, for $144 million.

FactSnippet No. 1,457,742

Teva Pharmaceuticals's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo.

FactSnippet No. 1,457,743

In October 2019, Teva Pharmaceuticals faced criticism for making a “business decision to discontinue the drug” Vincristine, essential for the treatment of most childhood cancers according to the Food and Drug Administration.

FactSnippet No. 1,457,744

In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to Sagent Pharmaceuticals for $40 million, as well as a further eight medicines to Dr Reddy's in a $350 million deal.

FactSnippet No. 1,457,745

Teva Pharmaceuticals sold a further 15 marketed generics, as well as three others which were close to market, for $586 million to Impax Laboratories.

FactSnippet No. 1,457,746

Also in June 2016 Teva Pharmaceuticals sold two abbreviated new drug applications to Indian pharmaceutical company Zydus Cadilla strengthen its US portfolio.

FactSnippet No. 1,457,747

In October 2016, Teva Pharmaceuticals has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds in cash.

FactSnippet No. 1,457,748

Teva Pharmaceuticals agreed to sell its Plan B One-Step and its brands of emergency contraception to Foundation Consumer Healthcare for $675 million in cash.

FactSnippet No. 1,457,749

Teva Pharmaceuticals holds patents on multiple drugs, including Copaxone, a specialty drug, now the world's best selling MS drug, and Azilect for treatment of Parkinson's disease.

FactSnippet No. 1,457,750

In March 2015, Teva Pharmaceuticals sold four anti-cancer compounds to Ignyta Inc for $41.

FactSnippet No. 1,457,751

In June 2021, Teva Pharmaceuticals agreed to pay $925M to settle allegations it had engaged in price fixing in Mississippi.

FactSnippet No. 1,457,752

In January 2022, Teva Pharmaceuticals agreed to pay $425M to settle allegations that it had concealed price fixing practices from shareholders.

FactSnippet No. 1,457,753

In May 2019, Teva Pharmaceuticals USA agreed to pay $85 million to the U S state of Oklahoma to settle allegations that it had been overprescribing opioids, marketing them as safe, and downplaying their addictive qualities.

FactSnippet No. 1,457,754

In February 2022, Teva Pharmaceuticals agreed to a $225 million settlement with the state of Texas to end claims that it fueled an opioid epidemic in the state by improperly marketing pain medicine.

FactSnippet No. 1,457,755

In 2018, Teva Pharmaceuticals USA recalled tablets containing valsartan due to the detection of N-nitrosodiethylamine which is a probable human carcinogen.

FactSnippet No. 1,457,756